Halberd Corporation (HALB) Research

Halberd Corporation is a biotechnology firm dedicated to pioneering therapies for neurodegenerative conditions. The company's therapeutic focus encompasses a broad range of serious illnesses, including post-traumatic stress disorder (PTSD) and chronic traumatic encephalopathy (CTE), Alzheimer's disease, Parkinson's disease, various forms of cancer, and disorders impacting the blood and cerebrospinal fluid. Established in 2009, Halberd Corporation operates from its headquarters in Jackson Center, Pennsylvania.

Market snapshot

Symbol
HALB
Price
$0.00
Day change
-9.09%
Market cap
$515.9K
P/E ratio
-15.90x
52-week range
0.0007-0.003
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biora Therapeutics, Inc. (BIOR)
  • Bio-Path Holdings, Inc. (BPTH)
  • Evofem Biosciences, Inc. (EVFM)
  • Helix BioMedix, Inc. (HXBM)
  • International Stem Cell Corporation (ISCO)
  • LiveCare, Inc. (LVCE)
  • Marizyme, Inc. (MRZM)
  • Neutra Corp. (NTRR)

Open Halberd Corporation (HALB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.